Clinical trial
A Study to Provide Access to Trabectedin in Participants With Locally Advanced…
NCT00210665 · Janssen Research & Development, LLC, Industry · No longer available
Key facts
| NCT number | NCT00210665 |
|---|---|
| Title | A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment |
| Official title | A Multicenter, Open-Label, Single-Arm Study of YONDELIS (Trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Status | No longer available |
| Study type | Expanded Access |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | Trabectedin |
| First posted | Sep 21, 2005 |
| Last update posted | Oct 10, 2017 |
| Countries | Canada, Israel, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: